Chemical inhibitors of MAGE-C3 can exert their influence by targeting critical components of signaling pathways that are essential for the protein's function. Dabrafenib, a BRAF inhibitor, can inhibit MAGE-C3 by interrupting the BRAF/MEK/ERK pathway, which is known to be essential for the post-translational modification or stabilization of various proteins, including the MAGE family. Similarly, Trametinib and Cobimetinib function as MEK inhibitors and can inhibit MAGE-C3 by disrupting downstream signaling of the RAS/RAF/MEK/ERK pathway, which is central to the regulation of protein activity within the cell. Vemurafenib, another BRAF inhibitor, can inhibit MAGE-C3 by obstructing the kinase activity necessary for its function or stability. LY3009120, targeting pan-RAF kinases, can inhibit MAGE-C3 by halting the RAF/MEK/ERK signaling cascade, thereby affecting proteins directly regulated by this pathway.
Encorafenib, as a BRAF inhibitor, can inhibit MAGE-C3 by interfering with MAPK pathway signaling mechanisms that MAGE-C3 may utilize. Binimetinib can inhibit MAGE-C3 by preventing MEK activation, thus impeding the signaling pathways that regulate MAGE-C3 activity. Sorafenib's multitargeted kinase inhibition can inhibit MAGE-C3 by disrupting various pathways, some of which may contribute to the post-translational modifications of MAGE-C3. Sunitinib, a receptor tyrosine kinase inhibitor, can inhibit MAGE-C3 by blocking critical signaling pathways that underpin the functional stability of proteins. Selumetinib, by specifically inhibiting MEK1/2, can inhibit MAGE-C3 by obstructing the MEK/ERK pathway, potentially a requirement for MAGE-C3's activity. Additionally, Pazopanib and Lenvatinib, as multikinase inhibitors, can inhibit MAGE-C3 by disrupting signal transduction through pathways involving receptor tyrosine kinases, which might be important for the regulation and function of MAGE-C3. These chemicals act on precise molecular targets within signaling cascades that are known to be important for the function of proteins such as MAGE-C3.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib inhibits multiple tyrosine kinases and can inhibit MAGE-C3 by disrupting signaling pathways that regulate protein stability and function, potentially affecting MAGE-C3. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
Lenvatinib, a multikinase inhibitor, can inhibit MAGE-C3 by impeding signal transduction through pathways that involve receptor tyrosine kinases, which could be important for MAGE-C3's regulation. | ||||||